Phencynonate S-isomer as a eutomer is a novel central anticholinergic drug for anti-motion sickness

Sci Rep. 2019 Feb 13;9(1):2000. doi: 10.1038/s41598-018-38305-9.

Abstract

To compare and evaluate the differences of stereoselective activity, the binding affinity, metabolism, transport and molecular docking of phencynonate isomers to muscarinic acetylcholine receptor (mAChR) were investigated in this study. The rotation stimulation and locomotor experiments were used to evaluate anti-motion sickness effects. The competitive affinity with [3H]-QNB and molecular docking were used for studying the interactions between the two isomers and mAChR. The stereoselective mechanism of isomers was investigated by incubation with rat liver microsomes, a protein binding assay and membrane permeability assay across a Caco-2 cell monolayer using a chiral column HPLC method. The results indicated that S-isomer was more effective against motion sickness and had not anxiogenic action at therapeutic doses. S-isomer has the higher affinity and activity for mAChR in cerebral cortex and acted as a competitive mAChR antagonist. The stereoselective elimination of S-isomer was primarily affected by CYP1B1 and 17A1 enzymes, resulting in a higher metabolic stability and slower elimination. Phencynonate S isomer, as a eutomer and central anticholinergic chiral drug, is a novel anti-motion sickness drug with higher efficacy and lower central side effect. Our data assisted the development of a novel drug and eventual use of S-isomer in clinical practice.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Aza Compounds / chemistry
  • Aza Compounds / therapeutic use*
  • Caco-2 Cells
  • Cell Line, Tumor
  • Cholinergic Antagonists / chemistry
  • Cholinergic Antagonists / therapeutic use*
  • Cytochrome P-450 CYP1B1 / metabolism
  • Glycolates / chemistry
  • Glycolates / therapeutic use*
  • Humans
  • Male
  • Mice
  • Mice, Inbred ICR
  • Microsomes, Liver / metabolism
  • Molecular Docking Simulation
  • Motion Sickness / drug therapy*
  • Motion Sickness / prevention & control*
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Muscarinic / drug effects*

Substances

  • 3-methyl-3-azabicyclo(3,3,1)nonanyl-9-alpha-yl-alpha-cyclopentyl-alpha-phenyl-alpha-glycolate
  • Aza Compounds
  • Cholinergic Antagonists
  • Glycolates
  • Receptors, Muscarinic
  • Cytochrome P-450 CYP1B1